US Pharm. 2015;40(6):21.
London, UK—Endo International has agreed to buy the privately held Par Pharmaceutical Holdings for $8.05 billion. Par’s product portfolio includes the generic drug entecavir for hepatitis B and also brand-name drugs like Megace ES for anorexia and Nascobal for vitamin B12 deficiency. Endo manufactures various generic and OTC medications, as well as the painkiller Percocet and erectile dysfunction treatment Stendra. The deal will create a specialty pharmaceutical company that would be one of the five largest generic-drug manufacturers based on U.S. sales.
To comment on this article, contact firstname.lastname@example.org.